Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 8, 2026Nature MedicineOpen Access

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

FGFrancesca GayWRW RoeloffzenMDMeletios A. Dimopoulos

Discussion

Loading...

Member takes

Overview

Phase 3 trial finds that Isa-KRd improves measurable residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma, suggesting enhanced treatment efficacy.

Key Points

  • The research aims to evaluate the effectiveness of the Isa-KRd regimen in achieving measurable residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
  • Randomized phase 3 trial with 302 patients aged ≤70 years
  • Comparison of isatuximab-carfilzomib-lenalidomide-dexamethasone (Isa-KRd) versus KRd
  • Focused on measurable residual disease negativity assessed by next-generation sequencing after consolidation
  • Post-consolidation MRD negativity significantly higher in Isa-KRd group at 10−5 sensitivity (77% vs 67%)
  • At higher sensitivity (10−6), MRD negativity was 68% for Isa-KRd vs 48% for KRd
  • Deep MRD responses were faster and more durable in the Isa-KRd group
  • Grade 3-4 adverse events were similar in both treatment arms

Cite This Study

Gay et al. (2026) studied this question.

synapsesocial.com/papers/69d5f05d74eaea4b11a79c4ehttps://doi.org/10.1038/s41591-026-04282-0
View Full Paper
Ask AI
Bookmark
Share